Cargando…
Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate)
Chronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global public health issue. Underlying this burden are the many complications of CKD, including mineral and bone disorders, anemia, and accelerated cardiovascular disease. Hyperphosphatemi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562046/ https://www.ncbi.nlm.nih.gov/pubmed/31134521 http://dx.doi.org/10.1007/s40265-019-01125-w |
_version_ | 1783426223569895424 |
---|---|
author | Ganz, Tomas Bino, Avi Salusky, Isidro B. |
author_facet | Ganz, Tomas Bino, Avi Salusky, Isidro B. |
author_sort | Ganz, Tomas |
collection | PubMed |
description | Chronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global public health issue. Underlying this burden are the many complications of CKD, including mineral and bone disorders, anemia, and accelerated cardiovascular disease. Hyperphosphatemia and elevated levels of fibroblast growth factor 23 (FGF23) have been identified as key independent risk factors for the adverse cardiovascular outcomes that frequently occur in patients with CKD. Auryxia(®) (ferric citrate; Keryx Biopharmaceuticals, Inc., Boston, MA, USA) is an iron-based compound with distinctive chemical characteristics and a mechanism of action that render it dually effective as a therapy in patients with CKD; it has been approved as a phosphate binder for the control of serum phosphate levels in adult CKD patients treated with dialysis and as an iron replacement product for the treatment of iron deficiency anemia in adult CKD patients not treated with dialysis. This review focuses on Auryxia, its mechanism of action, and the clinical attributes that differentiate it from other, non-pharmaceutical-grade, commercially available forms of ferric citrate and from other commonly used phosphate binder and iron supplement therapies for patients with CKD. Consistent with the chemistry and mechanism of action of Auryxia, multiple clinical studies have demonstrated its efficacy in both lowering serum phosphate levels and improving iron parameters in patients with CKD. Levels of FGF23 decrease significantly with Auryxia treatment, but the effects associated with the cardiovascular system remain to be evaluated in longer-term studies. |
format | Online Article Text |
id | pubmed-6562046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-65620462019-06-28 Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate) Ganz, Tomas Bino, Avi Salusky, Isidro B. Drugs Review Article Chronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global public health issue. Underlying this burden are the many complications of CKD, including mineral and bone disorders, anemia, and accelerated cardiovascular disease. Hyperphosphatemia and elevated levels of fibroblast growth factor 23 (FGF23) have been identified as key independent risk factors for the adverse cardiovascular outcomes that frequently occur in patients with CKD. Auryxia(®) (ferric citrate; Keryx Biopharmaceuticals, Inc., Boston, MA, USA) is an iron-based compound with distinctive chemical characteristics and a mechanism of action that render it dually effective as a therapy in patients with CKD; it has been approved as a phosphate binder for the control of serum phosphate levels in adult CKD patients treated with dialysis and as an iron replacement product for the treatment of iron deficiency anemia in adult CKD patients not treated with dialysis. This review focuses on Auryxia, its mechanism of action, and the clinical attributes that differentiate it from other, non-pharmaceutical-grade, commercially available forms of ferric citrate and from other commonly used phosphate binder and iron supplement therapies for patients with CKD. Consistent with the chemistry and mechanism of action of Auryxia, multiple clinical studies have demonstrated its efficacy in both lowering serum phosphate levels and improving iron parameters in patients with CKD. Levels of FGF23 decrease significantly with Auryxia treatment, but the effects associated with the cardiovascular system remain to be evaluated in longer-term studies. Springer International Publishing 2019-05-27 2019 /pmc/articles/PMC6562046/ /pubmed/31134521 http://dx.doi.org/10.1007/s40265-019-01125-w Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Article Ganz, Tomas Bino, Avi Salusky, Isidro B. Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate) |
title | Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate) |
title_full | Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate) |
title_fullStr | Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate) |
title_full_unstemmed | Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate) |
title_short | Mechanism of Action and Clinical Attributes of Auryxia(®) (Ferric Citrate) |
title_sort | mechanism of action and clinical attributes of auryxia(®) (ferric citrate) |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562046/ https://www.ncbi.nlm.nih.gov/pubmed/31134521 http://dx.doi.org/10.1007/s40265-019-01125-w |
work_keys_str_mv | AT ganztomas mechanismofactionandclinicalattributesofauryxiaferriccitrate AT binoavi mechanismofactionandclinicalattributesofauryxiaferriccitrate AT saluskyisidrob mechanismofactionandclinicalattributesofauryxiaferriccitrate |